Heartbeam, Inc. current report, 07 March 2022

Full document

HeartBeam, Inc. — Form 8-K Summary

Business Context and Reporting Period

HeartBeam, Inc. filed a Form 8-K dated March 7, 2022, with the report signed and filed on March 10, 2022. The company develops remote cardiac monitoring technology, including a telehealth 3D vector electrocardiogram (ECG) collection device intended to support remote heart attack or myocardial infarction monitoring.

Material Agreement and Development Plans

  • On March 7, 2022, HeartBeam entered into a professional services and co-development agreement with Triple Ring Technologies, Inc.
  • The five-phase expedited project covers design and development of HeartBeam’s Telehealth complete-solution 3D vector ECG collection device.
  • Planned activities include device builds for design verification and validation, packaging, and manufacturing technology transfer to a contract manufacturer that had not yet been identified.
  • The project was scheduled for completion in the fourth quarter of 2022 to support a 510(k) submission to the U.S. Food and Drug Administration.

Financial Metrics and Liquidity

This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, contract value, or other financial metrics related to the agreement.

Outlook, Risks, and Unusual Items

  • The stated development timeline and planned FDA 510(k) submission are objectives and remain subject to development, validation, manufacturing, regulatory, and other execution risks.
  • The contract manufacturer was to be named later, and the filing does not disclose the agreement’s financial terms or total expected project cost.
  • The filing contains only a brief description of the agreement; the complete rights and obligations are governed by the agreement filed as Exhibit 10.1.
  • HeartBeam issued a press release announcing the agreement on March 10, 2022.

Key Facts for Investors to Verify

  • Review Exhibit 10.1 for fees, payment terms, termination provisions, milestones, deliverables, and allocation of intellectual-property rights.
  • Verify whether the five-phase development project was completed in the fourth quarter of 2022 and whether a 510(k) submission was made.
  • Confirm the identity and status of the contract manufacturer and any related manufacturing-transfer costs.
  • Assess subsequent filings for changes to the development timeline, regulatory status, financing needs, and commercialization plans.